



### M&A Activity

- Over the previous few years M&A activity has been highly volatile. After a strong run, the deal environment came to a standstill in 2020 due to the pandemic. M&A activity spiked in 2021 due to government relief and pent-up investor demand, and then slowed again in 2022 and 2023 as financing costs crept up, geopolitical tensions rose, and growth in some sectors waned. After consecutive years of overall decline, M&A seems poised for a strong 2024 with near double-digit growth expected for North America in the second half of 2024 when compared to the first half of the year. At least one interest rate cut is expected this fall which along with low unemployment, strong consumer spending, and rising investment activity should provide a strong deal environment for the remainder of 2024. The pharmaceutical, life sciences and biotechnology sectors will continue to provide growth and opportunities for investors
- On May 30, 2024, Incyte announced that it completed its \$750 million acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.
- On May 25, 2024, AbbVie Inc. and Landos Biopharma, Inc. announced the completion of the previously announced definitive agreement under which AbbVie agreed to acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases, for approximately \$116 million.
- On March 25, 2024, Novo Nordisk and Cardior Pharmaceuticals announced that Novo Nordisk agreed to acquire Cardior for up to €1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved.
- On March 22, 2024, Gilead Sciences, Inc. announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. for approximately \$4.3 billion in total equity value. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.


### Trend in Industry Revenue Multiples<sup>1</sup>



### Trends in Revenue Growth<sup>1</sup>




### Relative Stock Price Returns<sup>2</sup>



<sup>1</sup> Calculated using aggregated data for AMGN, GILD, BIIB, CSL Limited, CELG, VRTX, REGN, ALXN, BMRN, INCY, ABBV, NOVO B, SGEN, IONS, ALNY, SRPT, BLUE, BGNE, MRNA, NBIX.

<sup>2</sup> Biotechnology is a custom, equal-weighted index constructed with the aforementioned companies.

### Purchase Price Allocation (PPA) % from Recent Transactions



### Notable M&A Deals

On May 22, 2024, Biogen Inc. and Human Immunology Biosciences, a privately held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases, announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire HI-Bio for \$1.15 billion upfront and up to \$650 million in potential milestone payments.

On May 20, 2024, Vertex Pharmaceuticals closed its acquisition of Alpine Immune Sciences for \$4.9 billion in cash, representing a 38% premium over Alpine's closing price on April 10, 2024. Alpine, based in Seattle, focuses on developing immunotherapies targeting cancer, kidney disease, and autoimmune and inflammatory conditions through engineered proteins influencing the body's immune response.

